FUSION SYSTEM
Biomea Fusion, Inc.
Application Filed: 2021-01-20
Trademark Application Details
Mark For: FUSION SYSTEM™ trademark registration is intended to cover the categories of
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
| Research |
OneLook
Acronym Finder
|
| Serial Number | 90478027 |
| Mark Literal Elements | FUSION SYSTEM |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | Trademark, Service Mark |
| Current Location | NEW APPLICATION PROCESSING 2021-01-23 |
| Basis | 1(b) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | Yes |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Alex Korona |
| Attorney Docket Number | 17184.007 |
Timeline
| 2021-01-20 | Application Filed |
| 2021-01-23 | Location: NEW APPLICATION PROCESSING |
| 2021-01-23 | Status: Live/Pending |
| 2021-01-23 | Status: New application will be assigned to an examining attorney approximately 3 months after filing date. |
| 2021-01-23 | Transaction Date |
Trademark Parties (Applicants & Owners)
| Party: |  Biomea Fusion, Inc. |
| Address | 726 Main Street Redwood City, CALIFORNIA UNITED STATES 94063 |
| Legal Entity Type | Corporation |
| Legal Entity State | DELAWARE |
Documents
 Drawing | JPEG | 2021-01-20 |
 TEAS Plus New Application | MULTI | 2021-01-20 |
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| International Codes: | 44 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Cellular function activating agents for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; Chemotherapeutics; Cytostatics for pharmaceutical purposes; Diagnostic preparations for medical purposes; Medical preparations for the treatment of cancer and metabolic diseases; Medicinal infusions for treating cancer and metabolic diseases; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for cancer and metabolic diseases; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of cancer and metabolic diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for cancer and metabolic diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer and metabolic diseases; Tumor suppressing agents |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2021-01-23 |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 FUSION SYSTEM 90478027 not registered Live/Pending |
Biomea Fusion, Inc. 2021-01-20 |
 FUSION SYSTEM 76114274 not registered Dead/Abandoned |
NEXICOR, LLC 2000-08-22 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 